Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: J Immunol. 2020 Jan 17;204(5):1386–1394. doi: 10.4049/jimmunol.1900742

Figure 3. Intratumoral CMP-001 therapy alone extends survival and slows local and distant tumor growth better than soluble G10 CpG ODN.

Figure 3.

A-B, Treatment schema and Kaplan-Meier curves of Balb/c mice primed and then implanted on one flank with A20 B lymphoma tumor cells, followed by IT CMP-001 or saline (data is from one experiment; n=10 mice per group). C-D, Treatment schema and Kaplan-Meier curves of Balb/c mice primed and then implanted on both flanks with A20 B lymphoma cells, followed by unilateral IT CMP-001, soluble G10 CpG ODN or saline. E, Tumor volumes (red=injected and black=noninjected) of individual mice after bilateral tumor implantation and treatment with unilateral IT CMP-001, soluble G10 CpG ODN or saline (data is representative of 2 replicate experiments; n=10 mice per group). Survival data were analyzed using the Logrank test.

HHS Vulnerability Disclosure